NCT01381393 - BONVIVA(Ibandronate) PMS(Post-marketing Surveillance ) | Biotech Hunter

Enrollment

659

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Osteoporosis

Interventions

DRUG

Ibandronate

Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Trial Locations (1)

137-701

GSK Investigational Site, Seoul